Eikon Therapeutics, Inc. (EIKN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$161.2M
Cash & Equivalents
$89.8M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$573M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | PHASE2 | Recruiting | 156 |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | PHASE2 | Recruiting | 130 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-01 | 8-K | Eikon Therapeutics, Inc. (EIKN) (CIK 0001861123) - EX-99.1 | EDGAR |